Role of bevacizumab therapy in the management of glioblastoma

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 97-104

  Peak, Scott J ^a   Levin, Victor A ^a  

^a Department of Neurosurgery and Neuroscience Kaiser Permanente ^*  (United States)

Author keywords

Central nervous system; Chemotherapy; Edema; VEGF

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CYTOTOXIC AGENT; ERLOTINIB; GELATINASE A; GELATINASE B; IRINOTECAN; MACROPHAGE ELASTASE; OSTEONECTIN; PROCARBAZINE; TEMOZOLOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; GENE EXPRESSION REGULATION; GENE TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION NECROSIS; REVIEW; SEIZURE; TREATMENT RESPONSE; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

EID: 77953406205     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: None     Document Type: Review

References (62)

1. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10): 997-1003.
2. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 2000-2004 Central Brain Tumor Registry of the United States; 2008.
3. Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113(7 Suppl):1953-1968.
4. Narod SA, Stiller C, Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer. 1991;63(6):993-999.
5. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 2008;41(4):278-286.
6. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med. 1991;174(5):1275-1278.
7. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843-845.
8. Ren Y, Tsui HT, Poon RT, et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer. 2003;107(1): 22-29.
9. Proescholdt MA, Heiss JD, Walbridge S, et al. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol. 1999;58(6):613-627.
10. Marchio S, Primo L, Pagano M, et al. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem.1999;274(39):27617-27622.
11. Nagashima G, Suzuki R, Hokaku H, et al. Graphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastoma. Surg Neurol. 1999;51(3):292-299.
12. Sandstrom M, Johansson M, Sandstrom J, Bergenheim AT, Henriksson R. Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression. Int J Dev Neurosci. 1999;17(5-6):473-481.
13. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for highgrade glioma. Nat Rev Neurol. 2009;5(11):610-620.
14. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(14):4589-4599.
15. Verhoeff JJ, van Tellingen O, Claes A, et al. Concerns about antiangiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009;9:444.
16. Criscuolo GR. The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor. Yale J Biol Med. 1993;66(4):277-314.
17. Risau W. Molecular biology of blood-brain barrier ontogenesis and function. Acta Neurochir Suppl. 1994;60:109-112.
18. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol. 1993;264(4 Pt 1):C995-1002.
19. Shibuya M. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor. Febs J. 2009;276(17):4636-4643.
20. Jiang BH, Agani F, Passaniti A, Semenza GL. v-Src induces expression of hypoxia-inducible factor 1 (Hif-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1- involvement of Hif-1 in tumor progression. Cancer Res. 1997;57(23): 5328-5335.
21. Gray MJ, Zhang J, Ellis LM, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005;24(19):3110-3120.
22. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21(13):2000-2008.
23. Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in highgrade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 2008;14(19):6042-6054.
24. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995;375(6532): 577-581.
25. Clarke K, Smith K, Gullick WJ, Harris AL. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer. 2001;84(10):1322-1329.
26. Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A. Normoxic and hypoxic regulation of vascular endothelial growth Factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer. 1999;81(1): 118-124.
27. Zhang Y, Zhang N, Dai B, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008;68(21):8733-8742.
28. Nabors LB, Gillespie GY, Harkins L, King PH. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenineand uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res. 2001;61(5):2154-2161.
29. Ido K, Nakagawa T, Sakuma T, Takeuchi H, Sato K, Kubota T. Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors. Neuropathology. 2008;28(6): 604-611.
30. Kerber M, Reiss Y, Wickersheim A, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008;68(18): 7342-7351.
31. McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68(4):487-506.
32. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843-7848.
33. Mathieu V, De Neve N, Le Mercier M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008;10(12):1383-1392.
34. Rapisarda A, Hollingshead M, Uranchimeg B, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009;8(7):1867-1877.
35. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 2005;7:369.
36. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
37. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
38. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
39. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977;47(3):329-335.
40. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
41. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
42. Levin VA. Chemotherapy of primary brain tumors. Neurol Clin. 1985;3(4):855-866.
43. Wilson CB, Gutin P, Boldrey EB, Drafts D, Levin VA, Enot KJ. Singleagent chemotherapy of brain tumors. A five-year review. Arch Neurol. 1976;33(11):739-744.
44. Levin VA, Wilson CB. Nitrosourea chemotherapy for primary malignant gliomas. Cancer Treat Rep. 1976;60(6):719-724.
45. Rodriguez LA, Prados M, Silver P, Levin VA. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer. 1989;64(12):2420-2423.
46. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588-593.
47. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant gliomas: a phase II study. J Clin Oncol. 1991;9(5):860.
48. Berger MS, Leibel SA, Bruner JM, Finlay JL, Levin VA. Primary Cerebral Tumors. In: Levin VA, ed. Cancer in the Nervous System. Second ed. New York: Oxford University Press; 2002:75-148.
49. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217-1222.
50. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271-278.
51. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71(5):1372-1380.
52. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75(1):156-163.
53. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;10(3):355-360.
54. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73(15):1200-1206.
55. Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. 2008;89(1):113-118.
56. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
57. Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol. 2008;88(3):339-347.
58. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007;67(2):323-326.
59. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217(2):377-384.
60. Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol. 2009;94(1):63-68.
61. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebocontrolled trial of bevacizumab therapy for radiation necrosis of the CNS. Int J Radiat Oncol Biol Phys. 2010. In press.
62. Higa GM, Abraham J. Biological mechanisms of bevacizumabassociated adverse events. Expert Rev Anticancer Ther. 2009;9(7): 999-1007.